Recurrence · patients with anorectal fistula
Radiofrequency showed no clear difference in recurrence compared with conventional fistula surgery (low certainty).
1 finding from 1 review
Incontinence · patients with anorectal fistula
Radiofrequency showed no clear difference in incontinence compared with conventional fistula surgery (moderate certainty).
1 finding from 1 review
Pain 1 month post treatment (VAS 0 to 10) · adults with chronic low‐back pain
1 finding from 1 review
Pain 1 to 6 months post treatment (VAS 0 to 10) · adults with chronic low‐back pain
1 finding from 1 review
Pain > 6 months post treatment (VAS 0 to 10) · adults with chronic low‐back pain
1 finding from 1 review
Function 1 month post treatment (ODI 0 to 100) · adults with chronic low‐back pain
1 finding from 1 review
Function 1 to 6 months post treatment (ODI 0 to 100) · adults with chronic low‐back pain
1 finding from 1 review
Function > 6 months post treatment (ODI 0 to 100) · adults with chronic low‐back pain
1 finding from 1 review
Pain 1 month post treatment (VAS 0 to 10) · adults with chronic low‐back pain
1 finding from 1 review
Pain 1 to 6 months post treatment (VAS 0 to 10) · adults with chronic low‐back pain
1 finding from 1 review
Function 1 month post treatment (ODI 0 to 100) · adults with chronic low‐back pain
1 finding from 1 review
Function 1 to 6 months post treatment (ODI 0 to 100) · adults with chronic low‐back pain
1 finding from 1 review
Mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus radiofrequency ablation changes mortality at maximal compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Cancer‐related mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus radiofrequency ablation changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
1 finding from 1 review
Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain 1 month post treatment (VAS 0 to 10)a · adults with chronic low‐back pain
1 finding from 1 review
Pain 1 to 6 months post treatment (VAS 0 to 10)a · adults with chronic low‐back pain
1 finding from 1 review
Pain > 6 months post treatment (VAS 0 to 10) · adults with chronic low‐back pain
1 finding from 1 review